Figure 4From: Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancerWestern blots show that combination treatment with JAKi and gefitinib caused attenuation of multiple signaling pathways. SKOV3 (A) and MDAH2774 (B) cells were treated with JAKi, gefitinib or the combination for 2 h and 24 h. Results are representative of 2–4 preparations.Back to article page